Brain Endothelial Cell-Cell Junctions: How to “Open” the Blood Brain Barrier

Svetlana M. Stamatovic\textsuperscript{1}, Richard F. Keep\textsuperscript{2,3} and Anuska V. Andjelkovic\textsuperscript{1,2,*}

\textsuperscript{1}Department of Pathology, \textsuperscript{2}Neurosurgery and \textsuperscript{3}Molecular and Integrative Physiology, University of Michigan, Ann Arbor MI 48109, USA

Abstract: The blood-brain barrier (BBB) is a highly specialized structural and biochemical barrier that regulates the entry of blood-borne molecules into brain, and preserves ionic homeostasis within the brain microenvironment. BBB properties are primarily determined by junctional complexes between the cerebral endothelial cells. These complexes are comprised of tight and adherens junctions. Such restrictive angioarchitecture at the BBB reduces paracellular diffusion, while minimal vesicle transport activity in brain endothelial cells limits transcellular transport. Under normal conditions, this largely prevents the extravasation of large and small solutes (unless specific transporters are present) and prevents migration of any type of blood-borne cell. However, this is changed in many pathological conditions. There, BBB disruption (“opening”) can lead to increased paracellular permeability, allowing entry of leukocytes into brain tissue, but also contributing to edema formation. In parallel, there are changes in the endothelial pinocytotic vesicular system resulting in the uptake and transfer of fluid and macromolecules into brain parenchyma. This review highlights the route and possible factors involved in BBB disruption in a variety of neuropathological disorders (e.g. CNS inflammation, Alzheimer’s disease, Parkinson’s disease, epilepsy). It also summarizes proposed signal transduction pathways that may be involved in BBB “opening”.

INTRODUCTION

“Good fences make good neighbors.” The blood-brain barrier (BBB) is a highly specialized structural, transport and biochemical (enzymatic) barrier, that mainly consists of microvascular endothelial cells and overlying astrocytic foot processes. It regulates the entry of compounds and cells between blood and brain and, thus, has a fundamental role in brain homeostasis. It also, though, forms a route of communication between circulating blood and underlying brain tissues [125,142,173]. Much of the structural barrier is due to the presence of tight junctions between the cerebral endothelial cells that limit paracellular diffusion. Those junctions, how they are regulated, how they are affected by disease states and how they can be manipulated therapeutically is the main focus of this review. Other reviews discuss other BBB properties (e.g. transport and enzymatic barrier properties) in depth.

BBB STRUCTURE: THE JUNCTIONAL COMPLEXES

BBB properties are primarily determined by endothelial junctional complexes consisting of tight junctions (TJ) and adherens junctions (AJ). It is generally accepted that TJ seal the interendothelial cleft forming a continuous blood vessel, while the AJ are important for initiating and maintaining endothelial cell-cell contact [60,142]. The tight junctions between BBB endothelial cells lead to high endothelial electrical resistance and low paracellular permeability. The electrical resistance is in the range of 1500-2000 \(\Omega\cdot\text{cm}^2\) (pial vessels) compared to 3-33 \(\Omega\cdot\text{cm}^2\) in other tissues [27,40].

TJ and AJ are composed of transmembrane proteins and cytoplasmic plaque proteins (Fig. 1, Table 1). The former proteins physically associate with their counterparts on the plasma membrane of adjacent cells, whereas the latter provide a link between transmembrane TJ/AJ proteins and the actin cytoskeleton but also participate in intracellular signaling [60,142].

Transmembrane proteins of the TJ include occludin, claudins (for example, claudin-3, -5, -12) and junctional adhesion molecule (JAM)-A, JAM-B and JAM-C [32,60,103]. Occludin was one of the first TJ transmembrane proteins described. Structurally, occludin contains two equal extracellular loops (44 amino acids), four transmembrane domains and three cytoplasmic domains: one intracellular short turn, a small N-terminal domain and a long carboxyl (C-) terminal [60,92,119,150]. It is thought that both of the extracellular loops provide the gate and fence-like structure of TJs, although the function of first extracellular loop is mostly involved in intercellular adhesion, while second loop mostly affects transendothelial electrical resistance [50,119]. The C-terminal domain (150 amino acids) of occludin is remarkably conserved between species and it is predicted to form a typical \(\alpha\)-helical coiled-coil structure [92,119]. Through this structure occludin can associate with ZO-1, ZO-2 and ZO-3, directly bind to F-actin, and interact with regulatory protein PKC\(\zeta\), tyrosine kinase c-Yes, PI3K and gap junction component connexin 26 [4,35,85,129,165,168]. As well as being involved in the integration and function of occludin in the TJ complex, this part of the molecule plays a critical role in paracellular channel formation and in mediating the endocytosis and trafficking of occludin [73,112,168]. The N-terminal site is critical for occludin function as an adhesion molecule and a N-terminal occludin mutant may be unable to fully oligomerize and completely assemble in TJ complexes [148].

Claudins are principal barrier-forming proteins that belong to the PMP22/EMP/MP20/claudin family of proteins...
Claudins have the same structural pattern: four membrane-spanning regions, two extracellular loops and two cytoplasmic termini: a very short internal N-terminal sequence (2-6 amino acids) and a longer internal C-terminal sequence (21-63 amino acids) [36,70]. The first extracellular loop (49-52 amino acids) influences paracellular charge selectivity, while the second extracellular loop (16-33 amino acids) is the receptor for a bacterial toxin [56,60,80,143]. The C-terminus possesses the binding site for the claudicin proteins ZO-1, ZO-2, ZO-3, MUPP1, PATJ through a PDZ motif [56,64,143]. Claudins function in the TJ complex is to limit paracellular ion movement selectively and this produces the high electrical resistance of the barrier [104,178]. Brain endothelial cells possess the claudin-5 and claudin-12 and possibly some other claudins [112,160]. Claudins present in brain endothelial cells may form pores of variable size (~10Å) which may be involved in transjunctional movement of water [17,104,121,178]. Claudin-5 deletion did not inhibit tight junction formation but did result in a size-selective increase in permeability [70,110].

JAMs (JAM-A, -B, -C) are members of the immunglobulin superfamily [15,16]. These molecules structurally are composed of a single membrane spanning domain, an extracellular domain, an extracellular N-terminus, and a short cytoplasmic C-terminus [15,16,159,186]. The extracellular region of JAMs consists of two IgG-like domains. These are often subclassified as C1-, C2-, V- and I-type based on the variable and constant regions of antibodies [15,159,186]. The extracellular domain appears to be subject of glycosylation, although the function of this is still unknown [186]. The N-terminal loop can be dimerized. The short C-terminus cytoplasmic tail (40 amino acids) contains a PDZ binding domain which facilitates interactions with TJ associated scaffold proteins such as ZO-1, AF-6, ASIP/Par3, and cingulin [74,124]. The cytoplasmic tail also contains consensus phosphorylation sites that may serve as substrates for PKC and PKA [36,123,165]. New evidence also suggests that this cytoplasmic tail may be involved in targeting JAM to intercellular junctions. In general, JAMs are expressed at the intracellular junctions of endothelial and epithelial cells and display different patterns of homo- and heterophilic adhesion [15,86,144]. Homophilic interactions are with molecules on the opposite cell, forming JAM dimers that are part of tight junction structure [15,144]. Heterophilic interactions, however, can occur between different JAM family members as well as other adhesion molecules (e.g. integrins) and their function is still unknown [86]. Regarding the function JAMs at the level of the TJ complex, these molecules are involved in promoting the localization of ZO-1, AF6, CASK and occludin at points of cell contact and, via targeting Par3, are involved in establishment of cell polarity [16,74]. There is also convincing evidence supporting a role for the members of JAM family in the migration of leukocytes across endothelial junctions [7,16,53].

The TJ cytoplasmic plaque proteins are subdivided depending on whether they contain a PDZ motif. PDZ containing proteins include members of the family membrane-associated guanylate-kinase (MAGUK) homologues (ZO-1, -2, -3), partitioning-defective proteins (Par)3, Par6, afidin/AF-6, etc [60,61,132]. These proteins contain a PDZ motif (80-90 amino acids) on the carboxyl terminal that can mediate interactions with other proteins, transmembrane proteins or with PDZ motifs on other proteins [60,61,152]. The PDZ domain is critical for clustering and anchoring of transmembrane proteins. Most of these proteins contain multiple PDZ domains, so they may act as scaffolds that bring together cytoskeleton, signaling and integral proteins at specific

Fig. (1). Structural features of the brain endothelial junctional complex.
| Junctional Complex | Proteins (Molecular Weight) | Localization | Function | Ref. |
|--------------------|-----------------------------|--------------|----------|-----|
| TJ transmembrane proteins | Occluding (~65 kDa) | membrane; multi-pass membrane protein; cell-cell contact, tight junction | formation and regulation of TJ paracellular barrier permeability; interacts with ZO-1, ZO-2, ZO-3, F-actin | [50,60,119] |
|  | Claudin 3, -5, -12 (~20-27 kDa) | membrane; multi-pass membrane protein; cell-cell contact, tight junction | tight junction-specific obliteration of the intercellular space; directly interacts with ZO-1, ZO-2 and ZO-3. | [60,70,111,178] |
|  | JAM-A, -B and –C (32-40 kD) | membrane; single-pass type I membrane protein; cell contact, tight junction | JAM-A (tight junction formation, neutrophile and monocytes transmigration; interaction with Par3); JAM-B lymphocytes transmigration; interaction with JAM-C); JAM-C (cell-cell adhesion, leukocytes transmigration; interaction with JAM-B) | [15,186,74,144] |
| TJ cytoplasmic plaque proteins | ZO-1, ZO-2, ZO3 (210-225kD, 160 kD, 130 kD) | cytoplasm; the cytoplasmic face of tight and adherens junction | ZO-1 (stabilization of junctions, signal transduction; interact with occludin, claudins, cingulin, ZO-3); ZO-2 (stabilization of TJ and AJ, interacts with occludin); ZO-3 (interacts with occludin, claudins and ZO-1) | [49,61,132,175] |
|  | Par-3, Par-6 (100-180kDa, ~37kDa) | cytoplasm; intracytoplasmic membrane; the cytoplasmic face of tight junctions | Tj assembly, the Par6-Par3 complex links GTP-bound Rho small GTPases to atypical protein kinase C proteins | [61,132] |
|  | Afadin/AF-6 (~205kDa) | cytoplasm; the cytoplasmic face of tight junctions | assembly of TJ and AJ; interaction JAMs, catenins, F-actin, nectin | [61,132] |
|  | Cingulin (108kD and 140 kD) | cytoplasm; the cytoplasmic face of tight junction | formation and regulation of the TJ permeability, anchoring the Tj proteins to actin-based cytoskeletons; interaction with ZO-1 and JAMs | [32,39] |
|  | 7H6 (~155kDa) | cytoplasm; colocalizes with actin stress fibers | F-actin cross-linking protein, anchor actin to other Tj and AJ proteins; interact with ZO-1, β-catenin | [146] |
|  | Rab3b, Rab13 (~25kD, –23kD) | lipid-anchor; the cytoplasmic face of tight junctions; cytoplasmic vesicle membrane | participation in polarized transport, assembly and/or activity of tight junctions | [112,169] |
|  | PKCζ, PKCμ (68-80kD, –74kD) | cytoplasm, membrane, endosome | cell polarization processes, biogenesis of Tj; interaction with Par3, Par6, Rac, Cdc42, actin cytoskeleton | [165,187] |
|  | G protein | membrane; multi-pass membrane protein; cell-cell contact, tight junction | Tj biogenesis, stabilization of TJ, regulation of permeability | [108] |
| Adherence Junction | Ve-cadherin (~130kD) | membrane; single-pass type I membrane protein, cell-cell and cell-matrix boundaries. | control the cohesion and organization of the intercellular junctions; | [114,142] |
|  | Catenin α, β, γ (plakoglobin), p120 (~100kD, 94kD,81 kD,120kD) | multiprotein cell-cell adhesion complex; cytoplasm; the cytoplasmic side of adherens junction; cytoskeleton, | with Ve-cadherin produces a complex which is linked to the actin filament network, and it is important for Ve-cadherin cell-adhesion properties | [69,114] |
regions of the plasma membrane [107,175]. For example, ZO-1 is thought to function as a multidomain scaffold that coordinates assembly of transmembrane and cytosolic proteins into TJ and/or regulates the activity of these proteins once they are assembled. ZO-1 binds to all three classes of TJ transmembrane proteins including occludin, claudins and CTX (IgG superfamily), but it also binds to 10 cytoplasmic proteins and various components of the cortical cytoskeleton [49,152,175]. In this case, ZO-1 is required for the normal kinetics of TJ assembly, for TJ specific localization and unique organization of transmembrane proteins [32,61].

PDZ lacking plaque proteins include as cingulin, 7H6, Rab13, ZONAB, AP-1, PKCζ, PKCλ, heterotrimeric G protein. These proteins exert a variety of functions at the TJ complex. Cingulin, for example, act as a cross link between TJ proteins (ZO-2, ZO-3, AF-6, JAM) and the actin-myosin cytoskeleton [32,39]. 7H6 mostly plays a role in TJ maintenance and maturation, while ZONAB is a transcription factor that regulates ErbB transcription and paracellular permeability [8,146]. Rab proteins (Rab13, Rab3b) have a role in docking and fusion of transport vesicles at the TJ complex [169]. PKCζ and PKCα are involved in regulation of polarization as well as in TJ assembly, while G proteins (Gα1o, Gα12, Go12, Gα13) co-immunoprecipitate with ZO-1 and play a role in accelerating TJ assembly and maintaining transendothelial electrical resistance [55,108,165,187].

Vascular endothelium cadherin (Ve-cadherin) is the major transmembrane protein of the endothelial AJ. A member of the large family of cadherins, it interacts homotypically in the presence of Ca²⁺. The AJ cytoplasmic plaque includes proteins of the catenin family (α, β, γ, p120) [15,114]. Ve-cadherin is an important determinant of microvascular integrity both in vitro and in vivo and together with catenin forms a complex that function as an early recognition mechanism between endothelial cells. [15,114,142,173]. It is believed that β- and γ-catenin link the cadherin to α-catenin which, in turn, couples the complex to the actin microfilament network of the cell skeleton [15,114,142,173]. A new p120 cadherin was recently identified [15]. Its role remains controversial in contrast to the above-mentioned classical catenins but high affinity binding of p120 catenin to Ve-cadherin suggest that it may regulate vascular permeability and affect BBB function [15,69,114].

BBB STRUCTURE: THE CYTOSKELETON

The brain endothelial cytoskeleton has a critical role in establishing interendothelial junctional integrity. The cytoskeleton is composed of three primary elements: actin microfilaments, intermediate filaments and microtubules [68, 85,156,182]. The actin microfilament system is focally linked to multiple membrane adhesion proteins including cadherin or occludin, glycocalyx components, functional intercellular proteins like zona occludens (ZO), catenins and focal adhesion complexes [85,167,182]. Short radial bands of F-actin: TJ and AJ actin-associated proteins are assembled to form a structure denoted as the actin-rich adhesion belt [68,156,182]. Actin structure is intimately involved in endothelial cells tension force generated via myosin light chain phosphorylation and actin stress fiber formation [78,151].

A second major element of the cytoskeletal structure of the brain endothelial cell is the microtubule system. Polymers of α- and β-tubulin form a lattice network of rigid hollow rods that span the cells in a polarized fashion from the nucleus to the periphery. Microtubules participate in rapid assembly of actin filaments and focal adhesion, isometric cellular contraction and/or increased transendothelial leukocyte migration. Some recent studies suggest that these functions are realized via interactions of microtubules with microfilaments [71,172].

Intermediate filaments, of which vimentin in the major protein in endothelial cells, are the third element involved in the cytoskeletal structure. The possible role of these filaments in cytoskeletal changes is still unclear although some recent studies indicate dynamic changes in vimentin during the reorganization of actin filaments and microtubules [85].

BBB FUNCTION: VESICULAR SYSTEM, ENZYMATIC BARRIER AND TRANSPORT

Before discussing how BBB junctions are regulated and affected by disease, it is necessary to put those junctions into the context of other BBB properties. These include the general paucity of vesicular transport at the BBB, the presence of enzymes that by degradation prevent the entry of a variety of compounds, and the presence of a wide range of transport systems. Because non-lipid soluble compounds only diffuse slowly across the BBB, the latter are necessary for both the entrance of nutrients into brain and the clearance of waste products from brain.

The cytoplasm of brain endothelial cell is of uniform thickness, with very few pinocytotic vesicles and a lack of fenestrations. The wall thickness of brain capillaries is approximately 40% of that in other types of endothelial cell [37]. It is speculated that this decrease in wall thickness could be an adaptation to the restrictive permeability of the BBB, allowing nutrients a shortened transport time to cross through the membrane and cytoplasm, and enter the brain parenchyma [37].

In general, brain endothelial cells have a very low number of vesicles under normal conditions compared to other types of endothelial cells. However, during some disease states (e.g. inflammatory conditions) the number of vesicles can increase. The classic type of caveole (Ω-shaped cell surface invagination, open or close) is one of the most predominant forms of vesicles [34, 97, 98, 154, 166]. Fusion between vesicles may eventually lead to the formation of transendothelial channels and/or vesicle/vacuolar organelles (VVO). Transendothelial channels correspond to chains of two or more fused vesicles that are open simultaneously on the luminal and abluminal side of endothelial cells [34,97,154, 166]. Besides that, channels made by one of the vesicle open on the both sides of endothelial cells can occur. VVO on the other hand are large collection of interconnected vesicles and vacuoles [98,166]. Fusion of vesicles, vacuole with luminal and abluminal plasma membranes create transcellular pathways confirmed in the several ultrastructural studies [29,37,98]. Brain endothelial cells also possess a well developed tubular system formed by membrane-bound tubules that intrude deeply into the endothelial cells from both the
luminal and abluminal poles. The tubular system also opens at the level of the lateral intercellular space and branches off in different directions forming an intracellular network resembling a tree-like network. This network is involved in the transport of circulating proteins and could be involved in transendothelial leukocyte migration [29,37,97].

The BBB is an enzymatic barrier, capable of metabolizing drug and nutrients [25,104]. These enzymes are principally directed at metabolizing neuroactive blood-borne solutes. Enzymes such as γ-glutamyl transpeptidase (γ-GTP), alkaline phosphatase, and aromatic acid decarboxylase are found at elevated concentrations in cerebral microvessels, yet are often in low concentration or absent in non-neuronal capillaries. These enzymes are often polarized between the luminal and abluminal membrane surface of brain endothelial cells. This concept is supported from several quantitative biochemical studies [18]. The enzymes γ-GTP and alkaline phosphatases are presented at the luminal endothelium [19].

The BBB possesses a wide array of transporters. Because of the occluded paracellular pathway, nutrients must cross the endothelial cell to gain access to brain from blood. Thus, for example, the BBB has very high levels of the glucose transporter GLUT1, and the large neutral amino acid transporter, LAT1, that facilitate movement of those nutrients from blood to brain [20,21]. There are also efflux transporters that move compounds from brain to blood. These transporters, such as P-glycoprotein and organic anion transporters, are involved in clearing waste products from the brain or preventing the entry of potentially neurotoxic compounds from blood to brain [41,94]. Other transporters are involved in ion homeostasis and the transport of signaling molecules between blood and brain. Many of these transporters have a polarized distribution at the cerebral endothelium. For example, Na⁺-K⁺-ATPase and the sodium-dependent neutral amino acid transporter (A-system) are associated with the abluminal portion of the endothelium [19]. Such structural, pharmacological and biochemical evidence for luminal and abluminal polarization of receptors, enzymes, and channels at the cerebral endothelium established the BBB to be a working, non-stagnant, membrane unequivocally evolved to maintain brain homeostasis.

Besides transporters, brain endothelial cells possess several ion channels, which control important endothelial functions. Ion channels are involved in the production and release of vasoactive factors (nitric oxide and prostacyclin), trafficking and secretion of haemostatic factors (von Willebrand, tissue type plasminogen activator) and enhancing flux of Ca²⁺ [46,81].

Ions or small molecules like amino acids and glucose are mostly transferred through the brain endothelial cells by transporters/carriers/channels present on the plasma membrane. Most macromolecules move across brain capillary endothelium by bulk phase non-receptor mediated endocytosis. For example, cationic macromolecules prefer uptake by clathrin coated membranes and pits and are subsequently delivered to and degraded in lysosomes [97]. In contrast, anionic molecules, which include most plasma proteins, undergo fluid internalization by apical caveolae and are shuttled to the basal side [97,115]. In general, pathological increases in BBB permeability are mostly associated with increased paracellular permeability although changes in transcellular flux may contribute.

**PHYSIOLOGY OF THE BBB: TRANSPORT THROUGH THE BBB (PARACELLULAR AND TRANSCELLULAR)**

These trans- and paracellular pathways differ with respect to physical properties: a) the transport across the transcellular pathway can be either passive or active while passage trough paracellular route is exclusive passive and it is driven by electrochemical, hydrostatic and osmotic gradients, b) compared to the transcellular route, the paracellular pathway is characterized by higher conductance and lower selectivity; c) paracellular transport is not rectified with the similar conductance and selectivity in either apical to basal or basal to apical directions; d) paracellular pathways have well defined values of electrical conductance as well as charge and size selectivity [14].

The paracellular permeability of the BBB is maintained by equilibrium between the contractile force generated at the endothelial cytoskeleton and adhesive forces produced at endothelial cell-cell junctions and cell-matrix contacts [58, 176]. A dynamic interaction among these structural elements controls the opening and closing the paracellular pathway and thus serves as a fundamental mechanism in regulation of the blood-brain exchange [58]. The unperturbed endothelial barrier has restrictive properties that are due primarily to the closed junctional complex. Factors which increase paracellular permeability act on the junctional complex resulting in the formation of minute intercellular gaps which can allow the passage of plasma proteins (e.g. albumin), fluid and leukocytes across the barrier. The processes by which interendothelial gaps are formed are the subject of intense investigation. There are two ongoing and probably simultaneous processes: changes in adhesive properties of TJ and AJ proteins and reorganization of the actin cytoskeleton.

The changes in adhesive property of TJ and AJ proteins are mostly correlated with alterations in their phosphorylation state. In general, the TJ proteins (e.g. occludin, ZO-1, ZO-2, and Claudin-5) are the phosphorylated proteins and changes in phosphorylation state affect their interaction, alter transmembrane protein localization and induce their redistribution [65,77,95,160,162]. Phosphorylation of TJ proteins can occur on amino acid residues Ser-, Thr-, and Tyr- although the exact position/sites of phosphorylation in the brain endothelial cells is still unknown. Analyzing published studies about the phosphorylation pattern of TJ and AJ protein in brain endothelial cells, it appears that type of phosphorylation mostly depends on the type of stimuli as well as the local microenvironment. For example, vascular endothelial growth factor and CCL2 induce Ser/Thr phosphorylation and redistribution of occludin and ZO-1 in murine brain endothelial cells, and oxygen mediators induce primarily Tyr-phosphorylation and reorganization of the TJ complex [65,67,77,162]. However, in conditions like calcium depletion, phorbol ester treatment or bacterial infection, TJ proteins (occludin) undergo dephosphorylation during Tj disruption rather than additional phosphorylation [33,91,113]. Similar to TJ proteins, AJ proteins like Ve-cadherin and β-catenin undergo...
Phosphorylated TJ and AJ proteins undergo redistribution, a critical event for the changes of adhesive contact between brain endothelial cells. A complete redistribution of TJ proteins can be seen at the time of lowest transendothelial electrical resistance and highest permeability coefficients for the tracers such as FITC-albumin, inulin and mannitol [162,163]. However there is still not firm evidence on how redistribution occurs. Simultaneous, and closely associated with junction protein modification, there is actin cytoskeleton reorganization [16,163]. Actin filament polymerization, actin myosin association and generation of intraendothelial contractile forces, results in “pulling in” of the contact surface between brain endothelial cells which may also result in the dislocation of transmembrane tight and adherence junction proteins [158].

**FACTORS INVOLVED IN PARACELLULAR AND TRANSCELLULAR BRAIN ENDOTHELIAL BARRIER “OPENING”**

Depending on the individual pathology, a variety of the factors are involved in altering BBB permeability. Several groups of mediators appear to have a prominent role in BBB disruption. These include a group of *vasogenic agents* including histamine, substance P, endothelin-1 and bradykinin; growth factors such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and transforming growth factors such as vascular endothelial growth factor (e.g., IL-1β, TNF-α) [1,6,43,45,99,115,136,137,164,190]. Potent serine/threonine kinases, such as protein kinase C (PKC), which have extracellular domains with one or more identifiable structural motifs, have binding sites for several growth factors including EGFR, Eph, FGF, PDGF or VEGF, while some others predominantly act to increase transcellular permeability (e.g., e.g., TNF-α) [1]. In addition, the duration of BBB disruption may differ between mediators. Some mediators, e.g. histamine, cause a rapid and transient opening of the BBB related to a fast cytoplasmic accumulation of Ca2+, while others, e.g. thrombin, cause prolonged opening of BBB related to robust changes in the endothelial cytoskeleton [176].

**SIGNAL TRANSDUCTION PATHWAYS REGULATING PARACELLULAR AND TRANSCELLULAR PERMEABILITY**

The regulation of paracellular permeability involves complex interactions between several agonist-activated signaling pathways and key structural components of the endothelial cells. The latter include, but are not limited to, TJ proteins. One of the most extensively studied regulators of TJ and TT-mediated permeability is protein kinase C (PKC). TJ proteins are phosphoproteins which possess several phosphorylation sites which could be affected during the brain endothelial TJ complex disassembly. PKCs are a family of serine/threonine kinases that regulate a variety of cell functions including proliferation, gene expression, cell cycle, differentiation, cytoskeletal organization, cell migration and apoptosis [133]. The PKC family includes isoforms (PKC-α, βΙ, βΙΙ, γ, δ, ε, η, μ, θ, λ, ζ, τ.), which are involved in signal transduction from membrane receptors to the nucleus [122,133]. Some of the PKC isoforms are denoted as critical molecules in phosphorylation of TJ proteins. For example, the activation of three PKC isoforms (PKC-α/βΙΙΙ, PKC (pan)-βΙΙ and PKC-ζ/λ) by viral gp120 leads to cytoskeleton alterations and increased monocyte migration [67,79,162]. Under hypoxic and post-hypoxic reoxygenation conditions and under the influence of endothelin-1, PKC-βΙΙΙ, PKC-γ, PKC- η, PKC-μ and PKC, regulate TJ disassembly [51,83,126]. Or CCL2 activation PKC isoforms PKCα and PKCζ induces phosphorylation of TJ proteins (occludin, claudin-5, ZO-1 and ZO-2) and brain endothelial barrier hyperpermeability [162]. However, it is very important to note that the activation of PKC isoforms is dependent on the type of activator as well as the type of the endothelial cells. Some PKC isoforms can have opposite roles in different types of endothelial cell. For example, in retinal endothelial cells, VEGF via PKCβII induces phosphorylation of occludin and increases permeability, but in brain endothelial cells this PKC isoform plays a protective role in VEGF-induced hyperpermeability [67, 161]. Therefore, it is critical to precisely define when and which type of PKC isoform is activated in brain endothelial cells under different conditions.

Besides serine/threonine residues, phosphorylation of tyrosine residues on TJ and AJ proteins also has a significant role in brain endothelial barrier disassembly. Protein tyrosine kinases (PTKs) are enzymes which catalyze the phosphorylation of tyrosine residues. There are two main classes of PTKs: receptor PTKs and cellular, or non-receptor, PTKs [120]. In regulation of brain endothelial barrier permeability, both classes of PTK play an important role. Receptor PTKs, which have extracellular domains with one or more identifiable structural motifs, have binding sites for several growth factors including EGFR, Eph, FGF, PDGF or VEGF, which
are involved in BBB hyperpermeability [12,28,120]. For example, VEGF via receptor Flt-1 and its downstream signaling molecules like phosphatidylinositol 3-kinase/Akt (PI3-K/Akt), nitric oxide synthases (NOS) and protein kinase G (PKG) can cause brain endothelial hyperpermeability and brain edema formation [41,181]. On the other hand, VEGF action via flk-1/KDR could induce specific Tyr-phosphorylation of the endothelial adherens junction components VE-cadherin, β-catenin, plakoglobin, and p120 [150]. Similar effects occur with vascular permeable factor (VPF) which via Flk-1 (VEGF-R2) and activation of membrane-associated kinases, such as Src and PI3K, induces increased BBB permeability and the development of local edema [150]. It is important to note that activation of PTK can also trigger activation and interaction with some other signaling molecules like nitric oxide (NO), ERK1/2, and PKC in relation to vascular permeability regulation.

In contrast to receptor PTKs, cellular PTKs are located in the cytoplasm, nucleus or anchored to the inner leaflet of the plasma membrane. They are grouped into eight families: Src, JAK, ABL, FAK, FPS, CSK, SYK and BTK [12,28,120]. Each family consists of several members. With the exception of homologous kinase domains (Src Homology 1, or SH1 domains), and some protein-protein interaction domains (SH2 and SH3 domains), they have little structural similarity [120]. The cellular PTKs are involved in cell growth, cell differentiation, and/or cell adhesion. Some members of this family (e.g. JAKs), have a role in phosphorylation of STAT transcription factors [54,120]. Reactive oxygen species are thought to primarily act through these kinases. For instance, reactive oxygen species generated during ischemia, brain injury, monocytes/neutrophil activation or alcohol exposure can activate matrix metalloproteinases (MMP-1, -2, and -9) and decrease tissue inhibitors of MMPs (TIMP-1 and -2) in a PTK-dependent manner [65,66]. The increase in MMPs and PTK activation is associated with degradation of endothelial basement membrane and enhanced tyrosine phosphorylation of TJ protein. Such changes may result in increased permeability and monocyte migration in stroke, in HIV-1 encephalitis, or in multiple sclerosis [20,140,170]. Pretreatment with PP1 could improve outcomes in the most of these conditions and strongly suggests a possible role of Src tyrosine kinase in BBB permeability regulation [65,66].

Mediators of oxidative stress also regulate brain endothelial permeability via a complex system of MAP kinases (p38, ERK1/2). MAP kinase could be a “nodal point” in, for example, PTK signaling [52]. However, it may also be a direct executor of TJ protein phosphorylation in conditions like exposure to 4-hydroxy-2-nonenal (4-HNE), one of the major biologically active aldehydes formed during inflammation and oxidative stress [174]. Human immunodeficiency virus-1 (HIV-1) Tat protein exerts similar effects, regulating expression of claudin-5 mRNA in brain endothelial cells via ERK1/2 activation but simultaneous activation of ERK1/2, PI3K, and nuclear factor-kB (NF-kB) mediated alterations and distribution of claudin-5 protein levels in Tat treated brain endothelial cells [3]. Chronic exposure to alcohol with simultaneous treatment with lipopolysaccharide (an inflammatory mediator) also triggers brain endothelial barrier “opening” and TJ protein phosphorylation via activation of ERK 1/2 and p38 kinase as well as Jun-N-terminal Kinase (JNK) and activation of Nfkb Rela-p50 [155].

In recent years, significant attention has focused on the family of small RhoGTPases as major regulators of TJ formation, maintenance and disruption. Rho, GEF-H1 a guanine nucleotide exchange factor for Rho, Rac, Cdc42 and ROCK are some of the member of RhoGTPase family [75]. They are known to mediate cytoskeletal contractile responses via myosin ATPase activity. For example, ROCK promotes phosphorylation of the regulatory light-chain of myosin (MLC) on Ser19 and Thr18 through phosphorylation of the myosin light-chain phosphatase (MLCP) and via blocking of MLC dephosphorylation. This site-specific phosphorylation of MLC in turn elevates myosin ATPase activity, leading to actin-myosin contraction [116,118]. This pathway has been described as a mechanism underlying “long-lasting” alterations in endothelial permeability caused by thrombin [176]. Some other factors, such as TGF-β, C5a-activated neutrophils, HIV infected monocytes, CCL2, ICAM-1, Cryptococcus neoformans, histamine and VEGF may also utilize this pathway [30,48,130,179]. Besides inducing specific actin filament polymerization (stress fiber formation) which turn generates contractile intraendothelial forces, RhoGTPase family members (Rho, ROCK) also induce phosphorylation of TJ and AJ proteins and their redistribution [26]. Two possibilities of how Rho and ROCK act are direct action on TJ and AJ complexes and indirect action via downstream activation of other signaling molecules (e.g. PKCa) [162].

The signaling pathways involved in regulating BBB permeability are still the subject of the very intensive investigation. Much current investigation is focused on defining the role of novel multiple signal pathways associated with BBB “opening” and how they interact at multiple levels. This is important in determining how signals are integrated and affect the phosphorylation of junction proteins and/or actin cytoskeletal remodeling.

LESSONS FROM BBB PATHOLOGY

Disruption of the BBB is generally believed to be harmful in most circumstances as it can cause the influx of leukocytes, potentially neuroactive compounds and water (edema) from blood. Many CNS diseases, including a diverse range of inflammatory diseases, diabetes, cancer, and microbial infection, cause such disruption. More often than not, this reflects a change in the TJ itself.

The most progressive BBB breakdown is associated with a diverse range of CNS inflammatory conditions. Whether the inflammation is primary, resulting from infection (meningitis, meningocencephalitis, encephalitis HIV infections) or an autoimmune disorder (multiple sclerosis), or secondary (as occurs following stroke or brain trauma), BBB breakdown is associated with several changes in brain endothelial phenotype (proinflammatory phenotype), junctional complex remodeling and a progressive increase in leukocyte infiltration [2,44,79,82,124,128,131,145,171]. Under some circumstances (stroke and brain trauma), vasogenic brain edema develops as a result of junction disruption [44,145]. A variety of inflammatory mediators participate in these pathological changes in brain endothelial junctional complexes. Dif-
ferent cytokines (IL-1β, TNF-α, INF-γ), chemokines (CXCL8, CCL2) matrix metalloproteinases (MMP-2, MMP9) and adhesion molecules (ICAM-1) play a role, which may be direct or indirect, via attraction of leukocytes [6,43,45,99,105,115, 127,137,164,190].

Neurodegenerative disease like Alzheimer or Parkinson disease may also display changes in BBB permeability [42,62]. Clinical and experimental studies show that BBB impairment is closely associated with increased rates of neurodegeneration in patients with Alzheimer disease and transgenic mice overexpressing APP695 in Tg2576 mice [62,87]. Increased BBB permeability is indeed hypothesized as a potential mechanism by which vascular β-amyloid accumulates in the brain parenchyma [23,87]. Transient BBB opening occurs in Parkinson’s disease, although most impairment occurs at the blood-cerebrospinal fluid barrier [42]. Again, such disruption is associated with transient secretion of inflammatory mediators.

Transient “opening” of BBB is also present before, during and after epileptic seizures. There a multiple factors involved in etiology of BBB impairment in epilepsy, including inflammatory mediators (epilepsy associated with stroke or brain trauma) and metabolic disorders [102].

Either primary or secondary (metastasis in the brain) brain tumors can induce BBB disruption. This is associated with disturbance of TJ complex which is manifested as a loss of staining for claudin-5, occludin and ZO-1. In addition, newly formed blood vessels in gliomas have abnormal TJ complexes with very low expression of some critical TJ proteins [93,145]. Alterations in BBB permeability are thought to be caused by accumulation of growth factors (VEGF or HGF) as well as proinflammatory cytokines [145]. One consequence of BBB disruption in brain tumors is the development of vasogenic edema which may be fatal.

Diabetes types II, hepatic encephalopathy (caused by hyperammonemia), or encephalopathy linked to thiamine deficiency are some of the metabolic disorders associated with BBB disturbance [149,170,183]. Accumulation of oxidative mediators, cytokines or matrix metalloproteinase MMP-9 are some of the factors that may be involved in BBB disruption in these conditions [72,76].

What lessons can be drawn from these neuropathological conditions? One common underlying factor for all of these neuropathological conditions is that inflammation and inflammatory mediators have a critical role in BBB disruption. These inflammatory factors mostly act focally/locally to induce paracellular opening (TJ complex remodeling). Inflammatory mediators and the process of inflammation may, therefore, be a good target for controlling BBB “opening” and “closing”.

NEUROPHARMACOLOGICAL SIGNIFICANCE OF BBB “OPENING”

There are two major reasons why is important to understand the mechanism underlying BBB “opening” and to be able to control such disruption. First, uncontrolled BBB “opening” may damage the brain parenchyma by enhancing leukocyte influx and vasogenic edema (e.g. in stroke, brain trauma or multiple sclerosis). Second, the normal BBB restricts the entry of potential therapeutic agents into brain. This, in large portion, has limited successful treatment of many severe CNS conditions such as brain tumors and neurodegenerative diseases [185]. The ability to modulate BBB permeability would enable physicians to prevent the adverse effects of BBB disruption in disease states or to enhance BBB permeability to permit the efficient transfer of drugs to brain.

Currently, the only therapeutic agents in use that improve BBB integrity are steroids [185]. They can have a marked effect on edema formation in tumors but are not effective in stroke. The precise mechanisms by which steroids (dexamethasone, hydrocortisone) affect the BBB are still uncertain. However, several in vitro and in vivo studies indicate that steroid therapy promotes BBB integrity through anti-inflammatory actions (decreased cytokine production and NFκB activation) as well as by stabilizing the TJ complex [139,184]. Some in vitro studies have indicated that hydrocortisone increases occludin mRNA and protein by acting on the occludin promoter region via the glucocorticoid receptor [139,184].

Inflammatory mediators appear to play a role in BBB disruption in many disease states and, therefore, inhibition of cytokines, chemokines or adhesion molecules is a potential therapeutic target [57]. Unfortunately, the use of antibodies to target cytokines and adhesion molecules in man has so far failed because of unwanted side effects [57]. There have been some promising results with chemokine inhibition, due to the fact that small peptide chemokine inhibitors display much less side effect.

Another potential therapeutic strategy is directed at stabilizing brain endothelial cell-cell interactions and the junctional complex. For example, S1p or SSeCKS mediators appear to decrease BBB permeability by acting primarily on TJ proteins [89,90]. Their activity is still the subject of intense investigation and it will be very interesting to see which signal molecules are involved in their actions on TJ proteins.

Another strategy, which is in the recent years has been gaining more attention, is targeting the signals molecules involved in remodeling junctional complexes. For example, targeting Rho, Rho kinase, MLCK, PTKs or PKC isoforms could be a promising strategy. RhoGTPases have significant effects on BBB integrity and the inflammatory response. They act as “on-and off-switches” and have a fundamental importance for increased permeability as well as in the time-dependent restoration of endothelial barrier function. Selective RhoGTPase inhibitors have produced promising results in some of the vascular as well as cerebrovascular disorders [30,182].

OPENING THE BBB FOR DRUG DELIVERY

In conditions such as brain tumors, neurodegenerative disorders like Alzheimer’s disease, Parkinson’s disease or different types of metabolic disorders with developing encephalopathy, therapeutic strategies are often limited by the inability of drugs to cross the BBB from blood to brain. There has, therefore, been much interest in devising methods
for disrupting the BBB. The ultimate goals of such methods are several: (i) there should be specificity in targeting the brain or preferably the diseased/injured part of the brain; (ii) the action should be brief in duration with the paracellular opening reverting back to control quickly; and (iii) the paracellular leak should be specific for the class of molecules one wishes to deliver.

There are several options for transiently disrupting the BBB. The most widely studied method involves intra-arterial injection of a hyperosmolar osmotic such as mannitol, which leads to endothelial cell shrinkage and opening of TJ. This method has been used extensively to deliver chemotherapeutic agents to gliomas, neuroectodermal tumors, CNS lymphomas, and brain metastases in animal models and patients by Newelt and colleagues [63,84,152]. Some specificity in targeting is achieved by injecting the hyperosmotic agent unilaterally into the cerebral circulation. Further data is still required before this technique gains widespread use.

Bradikinin and its analog RPM-7 (B2 receptor agonist) have also been investigated as potential inducers of transient BBB disruption [13,135]. Despite its longer half-life and greater selectivity, the use of RMP-7 in conjunction with chemotherapy showed no benefit in a randomized phase 2 trials for gliomas.

Other potential methods to induce transient “opening” of BBB are intra-arterial administration of alkylglycerola, which transiently increases the penetration of drugs or macromolecules across the BBB, and exposure of BBB to radiotherapy (20-30Gy) whilst chemotherapy is administered [47,84,138]. These strategies are under intense investigation in order to understand their mechanisms of action at the BBB and possible side effects.

A promising target to induce transient opening of the BBB for drug delivery may also be the signaling molecules involved in regulation of BBB permeability. We would like to point out that effect of Rho and Rho kinase in transient opening of brain endothelial barrier should be take in consideration for the further investigation of drugs deliver into brain.

An alternative strategy for drug delivery across the BBB focuses on transcytosis and transcellular permeability. Enhanced vesicular transport can be used for delivery compounds into the brain. Examples are: liposome-born therapeutic agents that show more transendothelial passage under hypothermic conditions and compounds which bind to lectins and via adsorptive vesicular transport are taken up into brain parenchyma [10,11,105,189]. Modulation of specific endothelial carrier proteins (transporters) is also a therapeutic target for enhancing drug delivery across the BBB. Such transporters may be involved in transport of compounds from blood to brain, in which case drugs which are substrates will have enhanced delivery (e.g. L-DOPA is a substrate for the L-system amino acid transporter). There are, however, also efflux transporters which clear compounds from the brain. P-glycoprotein (P-gp) is the major BBB efflux transporter and mice that lack P-gp have higher brain uptake of a wide range of drugs [96,180]. There has, therefore, been a major effort by drug companies to develop P-gp inhibitors to enhance the delivery of drugs to the brain. As yet, there have been no clinical trials that have shown a benefit of this approach to enhance drug delivery to brain.

From clinical and neuropathological point of view, controlling BBB permeability has tremendous importance in treatment of the devastating brain disorders. From the neuropharmacological point of view controlling BBB permeability should be effective, and without or with limited side effects. Thus, understanding BBB structure and the molecular mechanisms of regulating BBB permeability opens a new avenue of therapeutic strategies for most brain disorders.

CONCLUSION

Much exciting progress is being made in understanding the molecular basis of BBB paracellular permeability. Although some details remain obscure, the TJ is likely to be site where multiple cellular signaling pathways converge to regulate paracellular permeability. Due to this fact, further intensive investigation is needed to completely understand the mechanism of regulating permeability, but they promise to make important findings for the treatment of severe CNS diseases such as multiple sclerosis, stroke, infections and brain tumors.

REFERENCES

[1] Abbott, N.J. (2000) Inflammatory mediators and modulation of blood-brain-barrier permeability. Cell Mol. Neurobiol., 20, 131-147.
[2] Alvarez, J.L., Teale, J.M. (2006) Breakdown of the blood brain barrier and blood-ceilersosplinal fluid barrier is associated with different leukocyte migration in distinct compartments of the CNS during the course of murine NCC. J. Neuroimmunol., 173, 45-55.
[3] András, I.E., Pu, H., Tian, J., Deli, M.A., Nath, A., Hennig, B., Toborek, M. (2005) Signaling mechanisms of HIV-1 Tat-induced alterations of claudin-5 expression in brain endothelial cells. J. Cereb. Blood Flow Metab., 25(9), 1159-1170.
[4] Andreeva, A.Y., Piontek, J., Blisag, I.E., Utepebergov, D.I. (2006) Assembly of tight junction is regulated by the antagonism of conventional and novel protein kinase C isoforms. Int. J. Biochem. Cell. Biol., 38(2), 222-233.
[5] Annunziata, P., Cioni, C., Santonini, R., Paccagnini, E. (2002) Substance P antagonist blocks leakage and reduces activation of cytokine-stimulated rat brain endothelium. J. Neuroimmunol., 131(1-2), 41-49.
[6] Argaw, A.T., Zhang, Y., Snyder, B.J., Zhao, M.L., Kopp, N., Lee, S.C., Raine, C.S., Biosnan, C.F., John G.R. (2006) IL-1beta regulates blood-brain barrier permeability via reactivation of the hypoxia-angiogenesis program. J. Immunol., 177(8), 5574-5584.
[7] Aurand-Lions, M., Lamagna, C., Dangefelder, J.P., Wang, S., Herrera, P., Nourshargh, S., Imhof, B.A. (2005) Junctional adhesion molecule-C regulates the early influx of leukocytes into tissues during inflammation. J. Immunol., 174(10), 6406-6415.
[8] Balda, M.S., Matter, K. (2000) The tight junction protein ZO-1 and an interacting transcription factor regulate Ezhb-2 expression. EMBO J., 19(9), 2024-2033.
[9] Banks, W.A. (2005) Blood-brain barrier transport of cytokines: a mechanism for neuropathology. Curr. Pharm. Des., 11(8), 973-84.
[10] Banks, W.A., Ibrahimin, F., Farr, S.A., Flood, J.P., Morley, J.E. (1999) Effects of wheatgerm agglutinin and aging on the regional brain uptake of HIV-1GP120. Life Sci., 65(1), 81-89.
[11] Banks, W.A., Kastin, A.J., Brennan, J.M., Vallance, K.L. (1999) Adsorptive endocytosis of HIV-1GP120 by blood-brain barrier is enhanced by lipopolysaccharide. Exp. Neurol., 156(1), 165-171.
[12] Bannerman, D.D., Goldblum, S.E. (1999) Direct effects of endotoxin on the endothelium: barrier function and injury. Lab. Invest., 79(10), 1181-1199.
[13] Bartus, R.T., Elliott, P., Hayward, N., Dean, R., McEwen, E.L., Fisher, S.K. (1996) Permeability of the blood brain barrier by the
bradykinin agonist, RMP-7: evidence for a sensitive, autoreregulated, receptor-mediated system. Immunopharmacology, 33(1-3), 270-278.

Bazzoni, G. (2006) Endothelial tight junctions: permeable barriers of the vessel wall. Thromb. Haemost., 95(1), 36-42.

Bazzoni, G., Martínez-Estrada, O.M., Mueller, F., Nelboeck, P., Schmid, G., Bartfai, T., Dejana, E., Brockhaus, M. (2000) Homophilic interaction of junctional adhesion molecule. J. Biol. Chem., 275(40), 30970-30976.

Bazzoni, G., Dejana, E. (2004) Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol. Rev., 84(3), 869-901.

Belanger, M., Akashima, T., Ohtsuki, S., Yamaguchi, H., Ito, S., Terasaki, T. (2007) Hyperammonemia induces transport of tauin and creatine and suppresses claudin-12 gene expression in brain capillary endothelial cells in vitro. Neurochem. Int., 50(1), 95-101.

Betz, A.L., Goldstein, G.W. (1978) Polarity of the blood-brain barrier: neutral amino acid transport into isolated brain capillaries. Science, 202(4364), 225-227.

Betz, A.L., Firth, J.A., Goldstein, G.W. (1980) Polarity of the blood-brain barrier: distribution of enzymes between the luminal and antiluminal membranes of brain capillary endothelial cells. Brain Res., 192(1), 17-28.

Boado, R.J., Li, J.Y., Nagaya, M., Zhang, C., Partridge W.M. (1999) Selective expression of the large neutral amino acid transporter at the blood-brain barrier. Proc. Natl. Acad. Sci. USA, 96(21), 12079-12084.

Boado, R.J., Li, J.Y., Partridge W.M. (2004) Developmental regulation of the rabbit blood-brain barrier LAT1 large neutral amino acid transporter mRNA and protein. Pediatr. Res., 55(4), 557-560.

Boven, L.A., Middel, J., Verhoef, J., De Groot, C.J., Nottet H.S. (1998) Blood-brain barrier: neutral amino acid transport into isolated brain capillaries. Anat. Rec., 249(2), 461-466.

Bruewer, M., Hopkins, A.M., Hobert, M.E., Nusrat, A., Madara, J.L. (2004) RhoA, Rac1, and Cdc42 exert distinct effects on epithelial barrier via selective structural and biochemical modulation of junctional proteins and F-actin. Am. J. Physiol. Cell Physiol., 287(2), C327-C335.

Butt, H.J., Downing, K.H., Hansma, P.K. (1990) Imaging the membrane protein bacteriotox in with the atomic force microscope. Biophys. J., 58(6), 1473-1480.

Carbajal, J.M., Schaeffer, R.C. Jr. (1998) H2O2 and genistein differentially modulate protein tyrosine phosphorylation, endothelial morphology, and monolayer barrier function. Biochem. Biophys. Res. Commun., 249(2), 461-466.

Castejon, O.J. (1980) Electron microscopic study of capillary wall in human cerebral edema. J. Neuropathol. Exp. Neurol., 39(3), 296-328.

Chiba, Y., Ishii, Y., Kitamura, S., Sugiyama, Y. (2001) Activation of rho is involved in the mechanism of hydrogen-peroxide-induced lung edema in isolated perfused rabbit lung. Microvasc. Res., 62(1), 164-171.

Chen, S.H., Stins, M.F., Huang, S.H., Chen, Y.H., Kwon-Chung, K.J., Chang, Y., Kim, K.S., Suzuki, K, Jong, A.Y. (2003) Cryptococcus neoformans induces alterations in the cytoskeleton of human brain microvascular endothelial cells. J. Med. Microbiol., 52, 961-970.

Citi, S., Cordenonsi, M. (1998) Tight junction proteins. Biochim. Biophys. Acta, 1446(1), 1-11.

Clarke, H., Soler, A.P., Mullin, J.M. (2000) Protein kinase C activation leads to dephosphorylation of occludin and tight junction permeability increase in LLC-PK1 epithelial cell sheets. J. Cell Sci., 113, 3187-3196.

Clough, G., Michel, C.C. (1981) The role of vesicles in the transport of ferritin through frog endothelium. J. Physiol., 315, 127-42.

Clump, D.A., Qazi, I.H., Sudol, M., Flynn, D.C. (2005) c-Src response to growth factor activation. Growth Factors, 23(4), 263-72.

Comerford, K.M., Lawrence, D.W., Synnestvedt, K., Levi, B.P., Bartfai, T., Dejana, E., Brockhaus, M. (2002) Role of vasodilator-stimulated phosphorylase in PKA-induced changes in endothelial junctional permeability. FASEB J, 16(6), 583-587.

Coomer, B.L., Stewart, P.A. (1986) Three-dimensional reconstruction of vesicles in endothelium of blood-brain barrier versus highly permeable microvessels. Anat. Rec., 215(3), 256-261.

Coomer, B.L., Stewart, P.A. (1985) Morphometric analysis of CNS microvascular endothelium. Microvasc. Rev., 20(1), 99-115.

Cordenonsi, M., D’Atri, F., Hammar, E., Parry, D.A., Kendrick-Jones, J., Shore, D., Citi, S. (1999) Cingulin contains globular and coiled-coil domains and interacts with ZO-1, ZO-2, ZO-3, and myosin. J. Cell Biol., 147(7), 1569-1582.

Crone, C., Christensen, O. (1981) Electrical resistance of a capillary endothelium. J. Gen. Physiol., 77(4), 349-371.

Demeule, M., Regina, A., Jodoin, J., Laplante, A., Dagenais, C., Berthelet, F., Mohgrabi, A., Beliveau, R. (2002) Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vasc. Pharmacol., 38(6), 339-348.

Desai, B.S., Monahan, A.J., Carvey, P.M., Hendey, B. (2007) Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy. Cell Transplant, 16(3), 285-299.

Dimitrijevic, O.B., Stamatovic, S.M., Keep, R.F., Andjelkovic, A.V. (2006) Effects of the chemokine CCL2 on blood-brain barrier permeability during ischemia-reperfusion injury. J. Cereb. Blood Flow Metab., 26(6), 797-810.

Dimitrijevic, O.B., Stamatovic, S.M, Keep R.F, Andjelkovic, A.V. (2007) Absence of the chemokine receptor CCR2 protects against cerebral ischemia/reperfusion injury in mice. Stroke, 38(4), 1345-1353.

Dohgu, S., Yamauchi, A., Takata, F., Naito, M., Tsuruo, T., Higuchi, S., Sawada, Y., Kataoka, Y. (2004) Transforming growth factor-beta1 upregulates the tight junction and P-glycoprotein of brain microvascular endothelial cells. Cell Mol. Neurobiol., 24(3), 491-497.

Ennis, S.R., Ren, X.D., Betz, A.L. (1996) Mechanisms of sodium transport at the blood-brain barrier studied with in situ perfusion of rat brain. J. Neurochem., 66(2), 756-763.

Erdlenbruch, B., Alipour, M., Fricker G., Miller, D.S., Kugler, W., Eibi, H., Lakomek, M. (2003) Alkylglycerol opening of the blood-brain barrier to small and large fluorescence markers in normal and C6 glioma-bearing rats and isolated rat brain capillaries. Br. J. Pharmacol., 140(7), 1201-1210.

Ettienne, S., Adamson, P., Greenwood, J., Strosberg, A.D., Caen, T., Vachon, S., Courtois, F. (1998) G-protein signaling pathways associated with Rho activation in microvascular brain endothelial cells. J. Immunol., 161(10), 5755-5761.

Fanning, A.S., Little, B.P., Rahner, C., Utebergoven, D., Walther, Z., Anderson, J.M. (2007) The unique-5 and -6 motifs of ZO-1 regulate tight junction strand localization and scaffolding properties. Mol. Biol. Cell, 18(3), 721-731.

Feldman, G.J., Mullin, J.M., Ryan, M.P. (2005) Occludin: structure, function and regulation. Adv. Drug Deliv. Rev., 57(6), 883-917.

Fischer, S., Wiesnet, M., Marti, H.H., Renz, D., Schaper, W. (2004) Simultaneous activation of several second messengers in hyopxia-induced hyperpermeability of brain derived endothelial cells. J. Cell Physiol., 198(3), 359-369.

Fischer, S., Wiesnet, M., Renz, D., Schaper, W. (2005) H2O2 induces paracellular permeability of porcine brain-derived microvascular endothelial cells by activation of the p44/42 MAP kinase pathway. Eur. J. Cell Biol., 84(7), 687-697.

Fraemohs, L., Koenen, R.R., Ostermann, G., Heinemann, B., Wehr, C. (2004) The functional interaction of the beta 2 integrin lymphocyte function-associated antigen-1 with junctional adhesion molecule-A is mediated by the I domain. J. Immunol., 173(10), 6259-6264.
[54] Foster, D.A. (1993) Intracellular signalling mediated by protein-tyrosine kinases: networking through phospholipid metabolism. Cell Signal., 5(4), 389-399.

[55] Fukuhara, A., Shimizu, K., Kawakatsu, T., Fukuhara, T., Takai, Y. (2003) Involvement of nectin-activated Cdc42 small G protein in organization of adherens and tight junctions in Madin-Darby canine kidney cells. J. Biol. Chem., 278(51), 51885-51893.

[56] Furuse, M., Sasaki, H., Tsukita, S. (1999) Manner of interaction of heterogeneous claudin species within and between tight junction strands. J. Cell Biol., 147(4), 891-903.

[57] Furuya, K., Takeda, H., Azhar, S., McCarron, R.M., Chen, Y., Ruetzler, C.A., Wolcott, K.M., DeGraba, T.J., Rothlein, R., Hugli, T.E., de Zotto, G.J., Hallenbeck, J.M. (2001) Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intercellular adhesion molecule-1 antibody: a bedside-to-bench study. Stroke, 32(11), 2665-2674.

[58] Garcia, J.G., Schaphorst, K.L. (1995) Regulation of endothelial cell gap formation and paracellular permeability. J. Invest. Med., 43, 117-126.

[59] Ghearsi-Egea, J.F., Leiningher-Muller, B., Cecchelli, R., Fenstermacher, J.D. (1995) Blood-brain interfaces: relevance to cerebral drug metabolism. Toxicol. Lett., 82-83, 645-653.

[60] Gonzalez-Mariscal, L., Betanzos, A., Nava, P., Jaramillo, B.E. (2005) Tight junction proteins. Prog. Biophys. Mol. Biol., 81(1), 1-44.

[61] Gonzalez-Mariscal, L., Betanzos, A., Avila-Flores, A. (2000) MAGUK proteins: structure and role in the tight junction. Semin. Cell Dev. Biol., 11(4):315-324.

[62] Halliday, G., Robinson, S.R., Shepherd, C., Kril, J. (2000) Alzheimer's disease and inflammation: a review of cellular and therapeutic mechanisms. Clin. Exp. Pharmacol. Physiol., 27(1-2), 1-8.

[63] Haluska, M., Anthony, M.L. (2004) Osmotic blood-brain barrier modification for the treatment of malignant brain tumors. Clin. J. Oncol. Nurs., 8(3), 263-267.

[64] Hamazaki, Y., Itoh, M., Sasaki, H., Furuse, M., Tsukita, S. (2002) Multi-PDZ domain protein 1 (MUPP1) is concentrated at tight junctions in kidney cells.

[65] Halak, S., Pasquier, E., Braguer, D. (2005) Understanding microtubule dynamics for improved cancer therapy. Cell Mol. Life Sci., 62(24), 3039-3056.

[66] Hoffman, W.H., Casanova, M.F., Cudrici, C.D., Zakranskaia, E., Venugopalan, R., Nag, S., Oglesbee, M.J., Rus, H. (2007) Neuroinflammatory response of the choroid plexus epithelium in fatal diabetic ketoacidosis. Exp. Mol. Pathol., 83(1), 65-72.

[67] Ivanov, A.I., Nusrat, A., Parkos, C.A. (2004) Endocytosis of epithelial apical junctional proteins by a clathrin-mediated pathway into a unique storage compartment. Mol. Biol. Cell, 15(1), 176-188.

[68] Itoh, M., Sasaki, H., Furuse, M., Ozaki, H., Kita, T., Tsukita, S. (2001) Functional adhesion molecule (JAM) binds to PAR-3: a possible mechanism for the recruitment of PAR-3 to tight junctions. J. Cell Biol., 154(3), 491-497.

[69] Jaffe, A.B., Hall, A. (2005) Rho GTAPases: biochemistry and biology. Annu. Rev. Cell Dev. Biol., 21, 247-269.

[70] Jover, R., Rodrigo, R., Felipo, V., Insauti, R., Saez-Valero, J., Garcia-Ayallon, M.S., Suarez, I., Candela, A., Compan, A., Esteban, A., Cauli, O., Auso, E., Rodriguez, E., Gutierrez, A., Girona, E., Erceg, S., Berbel, P., Perez-Mateo, M. (2006) Brain edema and inflammatory activation in bile duct ligated rats with diet-induced hyperammonemia: A model of hepatic encephalopathy in cirrhosis. Hepatology, 43(6), 1257-1266.

[71] Kago, T., Takagi, N., Date, I., Takenaga, Y., Takagi, K., Takeo, S. (2006) Cerebral ischemia enhances tyrosine phosphorylation of occludin in brain capillaries. Biochem. Biophys. Res. Commun., 339(4), 1197-1203.

[72] Kanda, S., Miyata, Y., Kanetake, H. (2004) Role of focal adhesion formation in migration and morphogenesis of endothelial cells. Cell Signal., 16(11), 1273-1281.

[73] Kannmogne, G.D., Schall, K., Leibhart, J., Knipe, B., Gendelman, H.E., Persidsky, Y. (2007) HIV-1 gp120 compromises blood-brain barrier integrity and enhances monocyte migration across blood-brain barrier: implication for viral neuropathogenesis. J. Cereb. Blood Flow Metab., 27(1), 123-134.

[74] Katahira, J., Inoue, N., Horiguchi, Y., Matsuda, M., Sugimoto, N. (1997) Molecular cloning and functional characterization of the receptor for Clostridium perfringens enterotoxin. J. Cell Biol., 136(6), 1239-1247.

[75] Kimelberg, H.K. (2004) Water homeostasis in the brain: basic concepts. Neuroscience, 129(4), 851-860.

[76] Kirk, J., Plumb, J., Mirakurthi, M., McQuaid, S. (2003) Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. J. Pathol., 201(2), 319-327.

[77] Kostantinoulaki, M., Kouklis, P., Malik, A.B. (2003) Protein kinase C modifications of VE-cadherin, p120, and beta-catenin contribute to endothelial barrier dysregulation induced by thrombin. Am. J. Physiol. Lung Cell Mol. Physiol., 285(2L), L434-L442.

[78] Kroll, R.A., Neuwelt, E.A. (1998) Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery, 42(5), 1083-1099.

[79] Lai, C.H., Kuo, K.H., Leo, J.M. (2005) Critical role of actin in modulating BBB permeability. Brain Res. Brain Res. Rev., 50(1), 7-13.

[80] Lamagna, C., Meda, P., Mandicourt, G., Brown, J., Gilbert, R.J., Jones, E.Y., Kiefer, F., Raga, P., Imhof, B.A., Aurard-Lions, M. (2005) Dual interaction of JAM-C with JAM-B and alpha(Mbeta2 integrin) function in endothelial cell junctions and leukocyte adhesion. Mol. Biol. Cell, 16(10), 4992-5003.

[81] LaRue, B., Hogg, E., Sagare, A., Jovanovic, S., Maness, L., Maurer, C., Dean, R., Zlokovic, B.V. (2004) Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer’s Tg2576 mice. J. Neurosci. Methods, 138(1-2), 233-242.

[82] Lee, K.R., Kawai, N., Kim, S., Sagher, O., Hoff, J.T. (1997) Mechanisms of edema formation after intracerebral hemorrhage: effects of thrombin on cerebral blood flow, blood-brain barrier permeability, and cell survival in a rat model. J. Neurosurg., 86(2), 272-278.

[83] Lee, J.F., Zeng, Q., Ozaki, H., Wang, L., Hand, A.R., Hla, T., Wang, E., Lee, M.J. (2006) Dual roles of tight junction-associated protein, zona occludens-1, in sphingosine 1-phosphate-mediated endothelial hemostasis and barrier integrity. J. Biol. Chem., 281(39), 29190-29200.

[84] Lee, S.W., Kim, W.J., Choi, Y.K., Song, H.S., Son, M.J., Gelman, I.H., Kim, Y.J., Kim, K.W. (2003) SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier. Nat. Med., 9(7), 900-906.

[85] Leroy, A., Lauwaet, T., De Bruyne, G., Cornelissen, M., Mareel, M. (2000) Entamoeba histolytica disturbs the tight junction complex in human enteric T84 cell layers. FASEB J., 14(9), 1139-1146.

[86] Li, Y., Fanning, A.S., Anderson, J.M., Lavie, A. (2005) Structure of the conserved cytoplasmic C-terminal domain of occludin: identification of the ZO-1 binding surface. J. Cell Biol, 165(1), 151-164.

[87] Liebner, S., Fischmann, A., Rascher, G., Duffner, F., Grote, E.H., Kalbacher, H., Wolburg, H. (2000) Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol. (Berl.), 100(3), 323-331.
Liu, Y., Hu, M. (2000) P-glycoprotein and bioavailability-implication of polymorphism. *Clin. Chem. Lab. Med.*, 38(9), 877-881.

Lohmann, C., Krischke, M., Wegener, J., Galla, H.J. (2004) Tyrosine phosphate inhibition induces loss of blood-brain barrier integrity by matrix metalloproteinase-dependent - independent pathways. *Brain Res.*, 982(2), 184-196.

Loscher, W., Potschka, H. (2005) Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. *Prog. Neurobiol.*, 76(1), 22-76.

Lossinsky, A.S., Shivers, R.R. (2004) Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions. *Histol. Histopathol.*, 19(2), 535-564.

Lossinsky, A.S., Vorbrodt, A.W., Wisniewski, H.M. (1983) Ultra-cytocchemical studies of vesicular and canaliculic transport structures in the injured mammalian blood-brain barrier. *Acta Neuropathol. (Berl).* 61(3-4), 239-245.

Lum, H., Roebuck, K.A. (2001) Oxidant stress and endothelial cell dysfunction. *J. Physiol. Cell Physiol.*, 280, C179-C174.

Mackie, J.B., Weiss, M.H., Miao, W., Kirkman, E., Ghiso, J., Calero, M., Bading, J., Frangione, B., Zlolichikov, B.V. (1998) Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer's amyloid beta peptide in aged squirrel monkey with cerebral amyloglymph. *J. Neurochem.*, 76(1), 210-215.

MacIntyre, A., Abramov, R., Hammond, C.J., Hudson, A.P., Arkling, E.J., Little, C.S., Appel, D.M., Balin, B.J. (2003) Chlamydia pneumoniae infection promotes the transmigration of monocytes through human brain endothelial cells. *J. Neurosci. Res.*, 71(5), 740-750.

Marchi, N., Angelov, L., Masaryk, T., Fazio, V., Granata, T., Herrnandez, N., Hallen, K., Diglaw, T., Franic, L., Najig, I., Janigro, D. (2007) Seizure-promoting effect of blood-brain barrier disruption. *Epilepsia*, 48(4), 732-742.

Martín-Padura, I., Lostaglio, S., Schneemann, M., Williams, L., Romano, M., Fruscella, P., Panzeri, C., Stoppani, E., Ruco, L., Villa., A., Simmons, D., Dejana, E. (1998) Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. *J. Cell Biol.*, 142(1), 117-127.

Matter, K., Balda, M.S. (2003) Holey barrier: claudins and the regulation of brain endothelial permeability. *J. Cell Biol.*, 161(3), 459-466.

Matsumoto, T., Ikeda, K., Mukaide, N., Harada, A., Matsumoto, Y., Yamashita, J., Matushima, K. (1997) Prevention of cerebral edema and infarct in cerebral reperfusion injury by an antibody to interleukin-1. *Lab. Invest.*, 77(2), 119-125.

Matsumoto, T., Okamura, T., To, J., Takanaga, H., Ohtsuki, S., Sato, S., Yamaguchi, H., Kamoi, M., Asashima, T., Terasaki, T. (2007) Exogenous expression of claudin-5 induces barrier properties in cultured rat brain capillary endothelial cells. *J. Cell Physiol.*, 210(1), 81-86.

McNeil, E., Capaldo, C.T., Macara, I.G. (2006) Zonula occludens-1 function in the assembly of tight junctions in Madin-Darby canine kidney epithelial cells. *Proc. Natl. Acad. Sci. U.S.A.*, 103(2), 535-539.

Meyer, T.N., Hunt, J., Schwesinger, C., Denker, B.M. (2003) Galpha12 regulates epithelial cell junctions through Src tyrosine kinases: structure, substrate specificity, and drug discovery. *Bio-techniques*, 47(3), 197-223.

Nagafuchi, A. (2001) Molecular architecture of adherens junctions. *Curr. Opin. Cell Biol.*, 13, 600-603.

Narushima, I., Kita, T., Kubo, K., Yonetani, Y., Momochi, C., Inagaki, I., Nakashima, T. (1999) Contribution of endothelin-1 to disruption of blood-brain barrier permeability in dogs. *Naunyn Schmiedebergs Arch. Pharmacol.*, 360(6), 639-645.

Nelson, C.M., Pine, D.M., Tan, J.L., Chen, C.S. (2004) Vascular endothelial-cadherin regulates cytoskeletal tension, cell spreading, and focal adhesions by stimulating RhoA. *Mol. Biol. Cell.*, 15(6), 2943-2953.

Nitta, T., Hata, M., Gotoh, S., Seo, Y., Sasaki, H., Hashimoto, N., Furuse, M., Tsukita, S. (2003) Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. *J. Cell Biol.*, 161(3), 653-660.

Noma, K., Oyama, N., Liao, J.K. (2006) Physiological role of ROCKs in the cardiovascular system. *Am. J. Physiol. Cell Physiol.*, 290(3), C661-C668.

Oliva, J.L., Griser, E.M., Kazanietz, M.G. (2005) PKC isozymes and diacylglycerol-regulated proteins as effectors of growth factor receptors. *Growth Factors*, 23(4), 245-52.

Ozaki, H., Ishii, K., Ariai, H., Horiuchi, H., Kamamoto, T., Suzuki, H., Kita, T. (2000) Junctional adhesion molecule (JAM) is phosphorylated by protein kinase C upon platelet activation. *Biochem. Biophys. Res. Commun.*, 276(3), 873-878.

Quaglialore, V.J., Long, W.J., Scheld, W.M. (1986) Morphologic alterations of the blood-brain barrier with experimental meningitis in the rat. Temporal sequence and role of encapsulation. *J. Clin. Invest.*, 77(4), 1084-95.

Pardridge, W.M. (2007) Blood-brain barrier delivery. *Drug Discov. Today.*, 12(1-2), 54-61.

Park, J.Y., Takabara, N., Gabriele, A., Chou, E., Naruse, K., Su- zumu, K., Yamauchi, T., Ha, S.W., Meier, M., Rhodes, C.J., King, G.L. (2000) Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation. *Diabetes*, 49(7), 1239-1248.

Patnaik, R., Mohanty, S., Sharma, H.S. (2000) Blockade of histamine H2 receptors attenuate blood-brain barrier permeability, cerebral blood flow disturbances, edema formation and cell reactions following hyperthermic brain injury in the rat. *Acta Neurochir. Suppl.*, 76, 535-539.

Paul, R., Koedel, U., Winkler, F., Kieseier, B.C., Fontana, A., Kopf, M., Hartung, H.P., Pfister, H.W. (2003) Lack of IL-6 augments inflammatory response but decreases vascular permeability in bacterial meningitis. *Brain*, 126, 1873-1882.

Peng, B.H., Lee, J.C., Campbell, G.A. (2003) Phospholipase C-mediated regulation of tight junctions during monocyte migration across the blood-brain barrier in HIV-1 encephalitis. *Blood*, 107(12), 4770-4780.

Phares, T.W., Kean, R.B., Mkhheeva, T., Hooper, D.C. (2006) Regional differences in blood-brain barrier permeability changes and inflammation in the apathogenic clearance of virus from the central nervous system. *J. Immunol.*, 176(12), 7666-7675.

Ponting, C.P., Phillips, C., Davies, K.E., Blake, D.J. (1997) PDZ domains: targeting signalling molecules to sub-membranous sites. *BioEssays*, 19(6), 469-479.
PKC-interacting proteins: from function to pharmacology. *Trends Pharmacol. Sci.*, 25(10), 528-535.

[134] Potter, M.D., Barbero, S., Chercas, D.A. (2005) Tyrosine phosphorylation of VE-cadherin prevents binding of p120- and betacatenin and maintains the cellular mesenchymal state. *J. Biol. Chem.*, 280(36), 31906-31912.

[135] Prados, M.D., Schold, S.C. JR S.C., Fine, H.A., Jaekle, K., Hochberg, F., Mechtler, L., Fetel, M.R., Phuphanich, S., Feun, L., Janus, T.J., Ford, K., Graney, W. (2003) A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboptatin administered intravenously for the treatment of recurrent malignant glioma. *Neuro. Oncol.*, 5(2), 96-103.

[136] Poul, A., Bjernacki, K., Pouly, S., Nalbantoglu, J., Couture, R., Antel, J.P. (2000) Kinin B1 receptor expression and function on human brain endothelial cells. *J. Neuropathol. Exp. Neuro*, 59(10), 896-906.

[137] Reuss, B., Dono, R., Unsicker, K. (2003) Functions of fibroblast growth factor (FGF)-2 and FGF-5 in astroglial differentiation and blood-brain barrier permeability: evidence from mouse mutants. *J. Neurosci.*, 23(16), 6404-6412.

[138] Riccardi, R., Riccardi, A., Lasorella, A., Servidei, T., Mastrangelo, S. (1998) Cranial irradiation and permeability of blood-brain barrier to cytokines arabinoside in children with acute leukemia. *Clin. Cancer Res.*, 4(1), 69-73.

[139] Romero, I.A., Radewicz, K., Rubin, E., Michel, C.C., Greenwood, J., Couraud, P.O., Adamson, P. (2003) Changes in cytoskeletal and tight junctional proteins correlate with decreased permeability induced by dexamethasone in cultured rat brain endothelial cells. *Neurosci. Lett.*, 344(2), 112-116.

[140] Rosell, A., Ortega-Aznar, A., Alvarez-Sabin, J., Fernandez-Cadenas, I., Ribo, M, Molina, C.A., Lo E.H., Montaner, J. (2006) Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. *Stroke*, 37(6), 1399-1406.

[141] Rosenberg, G.A., Estrada, E.Y., Dencoff, J.E. (1998) Matrix Metuloproteinases and TIMPs are associated with blood brain barrier opening after reperfusion in rat brain. *Stroke*, 29, 2189-2195.

[142] Rubin, L.L., Staddon J.M. (1999) The biology of the blood-brain barrier. *Annu. Rev. Neurosci.*, 22, 11-28.

[143] Ruffer, C., Gerke, V. (2004) The C-terminal cytoplasmic tail of claudins 1 and 5 but not its PDZ-binding motif is required for apical localization at epithelial and endothelial tight junctions. *Eur. J. Cell Biol.*, 83(4), 155-144.

[144] Santos, S., Orlova, V.V., Song, K., Sachs, U.J., Andrei-Selmer, C.L., Chavakis, T. (2005) The homophilic binding of junctional adhesion molecule-1 mediates tumor cell-endothelial cell interactions. *J. Biol. Chem.*, 280(43), 36326-36333.

[145] Sato, S., Suga, S., Yunoki, K., Mihara, N., Michishita, N., Wang, Y., Matsuda, O., Kato-Mori, Y., Wada, T., Yamashita, T., Kojima, T., Sawada, N. (2004) Thtr(207) of claudin-5 is involved in size-selective opening of the endothelial barrier by cyclic AMP. *Exp. Cell Res.*, 300(1), 202-212.

[146] Spyridopoulos, I., Luedemann, C., Chen, D., Kearney, M., Chen, D., Murohara, T., Prinsep, N., Isner, J.M., Losordo, D.W. (2002) Divergence of angiogenic and vascular permeability signaling by VEGF: inhibition of protein kinase C suppresses VEGF-induced angiogenesis, but promotes VEGF-induced NO-dependent vascular permeability. *Arterioscler. Thromb. Vasc. Biol.*, 22(6), 901-906.

[147] Stamatovic, S.M., Dmitrijevic, O.B., Keep, R.F., Andjelkovic, A.V. (2006) Protein kinase Calpha-RhoA cross-talk in CCL2-induced alterations in brain endothelial permeability. *J. Biol. Chem.*, 281(13), 8379-8388.

[148] Stamatovic, S.M., Keep, R.F., Kuncel, S.L., Andjelkovic, A.V. (2003) Potential role of MCP-1 in endothelial cell tight junction ‘opening’: signaling via Rho and Rho kinase. *J. Cell Sci.*, 116, 4615-4628.

[149] Stamatovic, S.M., Shukai, P., Keep, R.F., Moore, B.B., Kuncel, S.L., Van Rooijen, N., Andjelkovic, A.V. (2005) Monocyte chemoattractant protein-1 regulation of blood-brain barrier permeability. *J. Cereb. Blood Flow Metab.*, 25(5), 593-606.

[150] Suzuki, A., Ishiyama, C., Hashiba, K., Shimizu, M., Ebnet, K., Ohno, S. (2002) αfPκC kinase activity is required for the asymmetric differentiation of periventricular pericyte junctional complex during epiphalial cell polarization. *J. Cell. Sci.*, 115, 3565-3573.

[151] Szul, E., Kaplin, A., Saucan, L., Palade, G. (1991) Protein traffic between distinct plasma membrane domains: isolation and characterization of vesicular carriers involved in transcytosis. *Cell*, 64(1), 81-89.

[152] Tao, Y.S., Edwards, R.A., Tubb, B., Wang, S., Bryan, J., McCrea, P.D. (1996) beta-Catenin associates with the actin-bundling protein fascin in a noncadherin complex. *J. Cell Biol.*, 134(5), 1271-81.

[153] Terai, T., Nishimura, N., Kanda, I., Yasiu, N., Sasaki, T. (2006) JARAB/MICAL-L2 is a junctional Rab13-binding protein mediating the endocytic recycling of occludin. *Mol. Biol. Cell.*, 17(5), 2465-2475.

[154] Tiwari, S.B., Amiji, M.M. (2006) A review of nanocarrier-based CNS delivery systems. *Curr. Drug Deliv.*, 3(2), 219-232.

[155] Troy, P.J., Clark, R.P., Kakarala, S.G., Burns, J., Silverman, I.E., Shore, E. (2005) Cerebral edema during treatment of diabetic ketoacidosis in an adult with new onset diabetes. *Neurocrit. Care*, 2(1), 55-58.

[156] Tung, M., Hsu, H.P., Wu, C.M., Liu, C.C., Lei, H.Y. (2001) Tu- mour necrosis factor-alpha causes an increase in blood-brain barrier permeability during sepsis. *J. Med. Microbiol.*, 50(9), 812-821.

[157] Tzima, E. (2006) Role of small GTPases in endothelial cytoskeletal dynamics and the shear stress response. *Circ. Res.*, 98(2), 176-185.
Ueno, M. (2007) Molecular anatomy of the brain endothelial barrier: an overview of the distributional features. Curr. Med. Chem., 14(11), 1199-1206.

Usatyuk, P.V., Parinandi, N.L., Natarajan, V. (2006) Redox regulation of 4-hydroxy-2-nonenal-mediated endothelial barrier dysfunction by focal adhesion, adherens, and tight junction proteins. J. Biol. Chem., 281(46), 35554-35566.

Utebergenov, D.I., Fanning, A.S., Anderson, J.M. (2006) Dimerization of the scaffolding protein ZO-1 through the second PDZ domain. J. Biol. Chem., 281(34), 24671-24677.

van Hinsbergh, V.W., van Nieuw Amerongen, G.P. (2002) Intracellular signalling involved in modulating human endothelial barrier function. J. Anat., 200(6), 549-560.

Van Itallie, C.M., Anderson, J.M. (2004) The role of claudins in determining paracellular charge selectivity. Proc. Am. Thorac Soc., 1(1), 38-41.

Varon, C., Basoni, C., Reuzeau, E., Moreau, V., Kramer, I.J., Genot, E. (2006) TGFbeta1-induced aortic endothelial morphogenesis requires signaling by small GTPases Rac1 and RhoA. Exp. Cell Res., 312(18), 3604-3619.

Vautier, S., Lacomblez, L., Chacun, H., Picard, V., Gimenez, F., Farinotti, R., Fernandez, C. (2006) Interactions between the dopamine agonist, bromocriptine and the efflux protein, P-glycoprotein at the blood-brain barrier in the mouse. Eur. J. Pharm. Sci., 27(2-3), 167-174.

Vogel, C., Bauer, A., Wiesnet, M., Preisnner, K.T., Schaper, W., Marti, H.H., Fischer, S. (2007) Flt-1, but not Flik-1 mediates hyperpermeability through activation of the PI3-K/Akt pathway. J. Cell Physiol., 212(1), 236-243.

Wang, A.I., Pollard, T.D., Herman, I.M. (1983) Actin filaments stress fibers in vascular endothelial cells in vivo. Science, 219, 867-869.

Watanabe, I., Tomita, T., Hung, K.S., Iwasaki, Y. (1981) Edematous necrosis in thiamine-deficient encephalopathy of the mouse. J. Neuropathol. Exp. Neurol., 40(4), 454-471.

Williams, L.A., Martin-Padura, I., Dejana, E., Hogg, N., Simmons, D.L. (1999) Identification and characterisation of human Junctional Adhesion Molecule (JAM). Mol. Immunol., 36(17), 1175-1188.

Yamanaka, T., Horikoshi, Y., Suzuki, A., Sugiyama, Y., Kita-mura, K., Maniwa, R., Nagai, Y., Yamashita, A., Hirose, T., Ishikawa, H., Ohno, S. (2001) PAR-6 regulates aPKC activity in a novel way and mediates cell-cell contact-induced formation of the epithelial junctional complex. Genes Cells, 6(8), 721-731.

Yuan, S.Y. (2002) Protein kinase signaling in the modulation of microvascular permeability. Vasc. Pharmacol., 39(4-5), 213-23.

Xie, Y., Ye, L., Zhang, X., Cui, W., Lou, J., Nagai, T., Hou, X. (2005) Transport of nerve growth factor encapsulated into liposomes across the blood-brain barrier: in vitro and in vivo studies. J. Control Release, 105(1-2), 106-119.

Zhang, Z.G., Zhang, L., Jiang, Q., Zhang, R., Davies, K., Powers, C., Bruggen, N., Chopp, M. (2000) VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J. Clin. Invest., 106(7), 829-838.